Adalvo is pleased to announce the successful DCP approval for Nintedanib 100mg & 150mg Soft Gel Capsules.
This product is developed based on two distinguished reference brands, Ofev and Vargatef. Ofev is indicated for the treatment of Idiopathic Pulmonary Fibrosis (IPF), Chronic Fibrosing Interstitial Lung Diseases with a Progressive Phenotype (PF-ILD), and Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD), and Vargatef addresses Non-Small Cell Lung Cancer (NSCLC).
The annual combined sales of both reference brands reached approximately $3.6 Bn in 2022 with a 3Y CAGR of 14%, according to IQVIA.
Based on our positive results, we expect to be amongst the first companies to market this product in all our major markets, with both indications upon expiry of relevant patents and exclusivities.
Partner up now!
At Adalvo, there are no half-measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.
paulo.rodriguez@adalvo.com – Europe
marta.puig@adalvo.com - South Europe
marc.nolasco@adalvo.com - West Europe
jose.rendueles@adalvo.com- North Europe, CEE & APAC
supreet.sharma@adalvo.com – North America & Canada
camila.reinoso@adalvo.com - LATAM (exc. Brazil)
bruno.alves@adalvo.com - Brazil & MENA
ajish.rajan@adalvo.com – Brands & Specialty Products
arni.baldursson@adalvo.com - Head of Global BD&L
Click on your preferred Business Partner and get in touch today!